Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Salim Yazji Insider Profile
4 Followers
Salim Yazji, CMO at Oncternal Therapeutics, holds 128.63K shares in Oncternal Therapeutics (Ticker: ONCT).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+5.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Salim Yazji does not currently own shares as a corporate insider.
A breakdown of Salim Yazji's holdings
Insider Roles
Salim Yazji does not currently hold a role as a corporate insider.
Roles that Salim Yazji holds in companies
Most Profitable Insider Trade
Stock:
Oncternal Therapeutics
(ONCT)
(ONCT)
Rating:Informative Buy
Date:Apr 14, 2023 - Apr 14, 2024
Return:+50.40%
The most profitable trade made by Salim Yazji
Salim Yazji's Trading History
List of latest transactions for each holding click on a transaction to see Salim Yazji's performance on stock
You May Also Like
Salim Yazji insider profile FAQ
What is the percentage of profitable transactions made by Salim Yazji?
The percentage of profitable transactions made by Salim Yazji is 50%.
What is the average return per transaction made by Salim Yazji?
The average return per transaction made by Salim Yazji is 5.10%.
What stocks does Salim Yazji hold?
Salim Yazji holds: ONCT stocks.
What was Salim Yazji’s latest transaction?
Salim Yazji latest transaction was an Uninformative Sell of $9.67K.
What was Salim Yazji's most profitable transaction?
Salim Yazji’s most profitable transaction was an Informative Buy of ONCT stock on April 14, 2023. The return on the trade was 50.40%.
What is Salim Yazji's role in Oncternal Therapeutics?
Salim Yazji's role in Oncternal Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.